First-Line Immuno-Oncology Therapies Up Survival in RCC With Brain Metastases
First-Line Immuno-Oncology Therapies Up Survival in RCC With Brain Metastases First-line immuno-oncology (IO)-based regimens and intensive focal therapies are associated with significantly prolonged overall survival (OS) among patients with brain metastases from renal cell carcinoma (RCC), new findings suggest. In a real-world study, median OS was 32.7 months for patients who received first-line IO-based combination […]